Avotaciclib (hydrochloride)

Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].

Product Specifications

Product Name Alternative

BEY1107 (hydrochloride)

UNSPSC

12352005

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/avotaciclib-hydrochloride.html

Purity

99.75

Solubility

DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=CC=NC(N)=N3.Cl

Molecular Formula

C13H12ClN7O

Molecular Weight

317.73

References & Citations

[1]Xie Z, et al. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. J Med Chem. 2022 May 12;65 (9) :6356-6389.|[2]Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17 (2) : 100900.